Blue Flower

Dr. Birner joined TVM Capital in 2000 as an investment manager and is currently managing partner at TVM Capital’s Munich and Montreal offices. He is responsible for numerous active investments in Europe as well as the United States. He currently serves as Chairman of the Board of Argos Therapeutics Inc. (Durham, North Carolina), leon-nanodrugs GmbH (Munich, Germany) and Spepharm Holdings BV (Amsterdam, The Netherlands) and is a member of the board of directors of Proteon Therapeutics, Inc (Boston, Massachusetts). Over many years, he was the chairman/vice Chairman of Direvo Biotech AG (Cologne, Germany) and Jerini AG (Berlin, Germany), which were acquired in 2008 by Bayer HealthCare AG and Shire Ltd., respectively.

Before joining TVM Capital, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca. Hubert joined Zeneca from McKinsey & Company's European Health Care and Pharmaceutical practice. As a management consultant, he gained extensive experience in management in research and development, marketing and sales,joint venture structuring and business development. Dr. Birner was also an Assistant Professor for biochemistry at the Ludwig-Maximilians-University in Munich. In this capacity, he directed various research projects for large pharmaceutical companies. He holds an MBA from Harvard Business School and a doctoral degree in biochemistry from Ludwig-Maximilians-University Munich, where he graduated summa cum laude. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases.

Dr. J. Donald deBethizy served as president and chief executive officer of Santaris Pharma A/S, Denmark and U.S., until September 2014, when the company was sold to Roche. He served as executive chairman of Contera Pharma ApS until it was sold to Bukwang Pharma in November 2014. Don was co-founder and chief executive officer of Targacept, Inc., U.S., a public biotechnology company listed on NASDAQ. He completed a postdoctoral fellowship at the Chemical Industry Institute of Toxicology at Research Triangle Park, NC, and is a Diplomate of the American Board of Toxicology. Dr. deBethizy has held adjunct appointments at Wake Forest University Babcock School of Management, Wake Forest University School of Medicine and Duke University. He also currently serves on the board of directors of Newron Pharmaceuticals SpA, arGEN-X N.V., Rigontec GmbH, and Serendex Pharmaceuticals A/S.

Mr. Köhler joined DEWB Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG in August 2000 and has served as member of the board of directors of DEWB Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG since June 2005. Prior to his activity at DEWB Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG, Mr. Köhler was a risk management consultant at Commerzbank AG, where he led projects in the area of company reorganizations, mergers and acquisitions and turnaround-situations. He began his career as a management consultant at KPMG in the field of financial services. Currently, he also serves on the board of directors of Nanotron Technologies Ltd., LemnaTec GmbH, DirectPhotonics Industries GmbH. He holds an university diploma in economics as "Diplom-Kaufmann".

Dr. Litzka has been a partner with Paris-based Edmond de Rothschild Investment Partners (EdRIP) since 2006. He invests primarily in European biotechnology and medtech companies as well as to some extent in the United States. In addition to being a member of the supervisory board of NOXXON Pharma AG, he currently serves on the board of Allecra Therapeutics GmbH, Probiodrug AG, SuperSonic Imagine and JenaValve Technology GmbH, and served on the board of Novexel, Sapiens and Endosense up until their respective acquisitions. Before joining EdRIP, Olivier Litzka spent six years with 3i’s life science venture capital practice, based first in Munich and then in Paris. In this position, he served on the boards of several portfolio companies and made a range of international investments. Before joining 3i in 2000, he worked as a strategy consultant with Mercer Management Consulting for several years, both in Munich and Paris. Dr. Litzka holds a Ph.D. in molecular microbiology from the University of Munich.

Dr.  PetitBon  is  general  partner  and  co-founder  of  Kreos  Capital  where  he  focuses  on  healthcare  investments. Prior to co-founding Kreos, Maurizio was managing partner of PMA Europe, London, a consulting partnership focused on  assisting  private  equity  firms  and  corporate  clients  in  evaluating  investment  opportunities  in  technology  companies. Prior to that, he was principal consultant at SRI International, in MenloPark, California and London where he advised a number  of  U.S.,  European  and  Japanese  technology  companies  on  business  development  and  M&A  strategies. He also held a number of managerial positions at Emerson Electric, Digital Equipment and Xerox. Dr. PetitBon holds a doctor’s degree in mechanical engineering from the University of Rome and a Master in Business Administration from INSEAD in Fontainebleau, France.

Dr. Wenninger has over 30 years of experience in research and development, financial, business, and operating management in the pharmaceutical industry. He joined Bayer Pharma in 1968, where he held executive management positions in Germany, the United States and Europe within the life science business of Bayer AG. From 1994 to 2000, Dr. Wenninger served as a member of the management board of Bayer AG. Following his retirement at Bayer, Dr. Wenninger has been involved in the strategic positioning and development of several companies and organizations. He currently serves on the advisory group for the board of Novo A/S, DK. He has been a member of the executive committee of the German Cardiac Research Foundation, the executive committee of the Robert-Koch-Foundation, and until recently was a long time member of the board of trustees of the German Cancer Research Center. Dr. Wenninger graduated from the Ludwig-Maximilians-University Munich in veterinary medicine with a Ph.D. and with a degree in economics as "Diplom-Kaufmann".